Market Overview:
The global breast cancer diagnostic and drug technologies market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of breast cancer, technological advancements in the field of diagnostics and drugs, and rising awareness about early diagnosis and treatment options for breast cancer. The mammography segment is expected to account for the largest share of the global breast cancer diagnostic and drug technologies market in 2018. This segment is driven by the increasing demand for early detection methods for breast cancer, technological advancements in mammography equipment, and growing awareness about mammography as a screening tool for early detection of breast cancer. The ductal carcinoma of Breast segment is expected to account for the largest share of the global invasive ductal carcinoma application market in 2018. This growth can be attributed to factors such as rising incidence rates of ductal carcinoma among women worldwide, growing adoption rateof advanced diagnostic techniques such as MRI-guided biopsyand PET/CT scansfor detecting early-stage tumors,and availabilityof targeted therapiesfor treating advanced stages oftumors.
Product Definition:
Breast cancer diagnostic and drug technologies are used to diagnose and treat breast cancer. They include imaging technologies, such as mammography and ultrasound, as well as drugs, such as chemotherapy agents. The importance of breast cancer diagnostic and drug technologies is that they allow for the early diagnosis of breast cancer, which increases the chances for successful treatment.
Mammography:
Mammography is the technique of using optical instruments to view the breast area in order to detect cancer. The growth factor for this market is increasing awareness about breast cancer and its symptoms, early detection with screening techniques such as mammography, and rising government initiatives. For instance; In October 2014, Health Canada announced funding of USD 2 million for five years towards research into better screening methods for women at high risk of developing breast cancer.
Biopsy:
A Biopsy is a medical procedure used to obtain tissue or samples from the body for examination under a microscope. It's major use in breast cancer diagnosis is to determine if there are any abnormal cells present in the milk ducts of the breast, which may lead to cancer. The other uses include testing for skin lesions, skin tags, and cancers; evaluation of liver tumors; tests for bone metastasis; and removal of skin grafts.
Application Insights:
Based on application, the market is segmented into ductal carcinoma of breast, lobular carcinoma, invasive ductal carcinoma and triple negative breast cancer. In 2017, theductal carinoma of breast held a major share in the overall revenue due to increasing incidence rates globally. Ductal Carcinoma of Breast (DCC) is further sub-segmented into DCIS and non-metastatic DCC. Metastatic disease is responsible for more deaths than primary tumor in women with advanced cancer as well as after mastectomy due to increased risk of recurrence post surgery.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high awareness levels, and availability of technologically advanced products. Moreover, increasing government funding for cancer research is also expected to drive growth during the forecast period. Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China and India. In addition, a rise in consumer awareness regarding early diagnosis will further boost revenue generation prospects within this region during the same period.
Moreover, an increase in spending capacity among people due to growing economy will help them avail technologically advanced diagnostic procedures at affordable prices thereby driving regional demand over time ( ). Latin America has witnessed significant gains owing to increased government spending on healthcare sector coupled with economic development within this region ( ).
Growth Factors:
- Increasing incidence of breast cancer: The incidence of breast cancer is increasing at a rapid pace across the globe. This is primarily attributed to the changing lifestyle and dietary habits, growing population, and aging population. According to the American Cancer Society, around 246,660 new cases of invasive breast cancer are expected to be diagnosed in women in 2017 in the U.S., and around 40,610 women are expected to die from this disease.
- Growing awareness about early detection: There is a growing awareness among people about the importance of early detection of breast cancer for better treatment outcomes. This has led to an increase in demand for diagnostic and screening technologies for early detection of this disease.
- Technological advancements: The development of novel diagnostic and therapeutic technologies has been a key growth driver for the global Breast Cancer Diagnostic and Drug Technologies market over the past few years. These technologies are helping healthcare professionals detect breast cancer at an earlier stage as well as improve treatment outcomes for patients with this disease.. For instance, Roche’s Herceptin (trastuzumab) drug is used for treating HER2-positive metastatic or locally advanced breast cancers that have not responded to other treatments or have come back after treatment..
Scope Of The Report
Report Attributes
Report Details
Report Title
Breast Cancer Diagnostic and Drug Technologies Market Research Report
By Type
Mammography, Biopsy, Other
By Application
Ductal Carcinoma of Breast, Invasive Ductal Carcinoma, Lobular Carcinoma, Triple Negative Breast Cancer
By Companies
Abbott, Roche, BioMerieux, Becton Dickinson, GE Healthcare, Hologic, Philips, PerkinElmer, Quest Diagnostics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Breast Cancer Diagnostic and Drug Technologies Market Report Segments:
The global Breast Cancer Diagnostic and Drug Technologies market is segmented on the basis of:
Types
Mammography, Biopsy, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ductal Carcinoma of Breast, Invasive Ductal Carcinoma, Lobular Carcinoma, Triple Negative Breast Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Roche
- BioMerieux
- Becton Dickinson
- GE Healthcare
- Hologic
- Philips
- PerkinElmer
- Quest Diagnostics
Highlights of The Breast Cancer Diagnostic and Drug Technologies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Mammography
- Biopsy
- Other
- By Application:
- Ductal Carcinoma of Breast
- Invasive Ductal Carcinoma
- Lobular Carcinoma
- Triple Negative Breast Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Breast Cancer Diagnostic and Drug Technologies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Breast cancer diagnostic and drug technologies are the latest advances in the diagnosis and treatment of breast cancer. These technologies can help identify breast cancers early, improve the accuracy of diagnoses, and develop more effective treatments.
Some of the key players operating in the breast cancer diagnostic and drug technologies market are Abbott, Roche, BioMerieux, Becton Dickinson, GE Healthcare, Hologic, Philips, PerkinElmer, Quest Diagnostics.
The breast cancer diagnostic and drug technologies market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Breast Cancer Diagnostic and Drug Technologies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Breast Cancer Diagnostic and Drug Technologies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Breast Cancer Diagnostic and Drug Technologies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Breast Cancer Diagnostic and Drug Technologies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Breast Cancer Diagnostic and Drug Technologies Market Size & Forecast, 2018-2028
4.5.1 Breast Cancer Diagnostic and Drug Technologies Market Size and Y-o-Y Growth
4.5.2 Breast Cancer Diagnostic and Drug Technologies Market Absolute $ Opportunity
Chapter 5 Global Breast Cancer Diagnostic and Drug Technologies Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Type
5.2.1 Mammography
5.2.2 Biopsy
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Breast Cancer Diagnostic and Drug Technologies Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Applications
6.2.1 Ductal Carcinoma of Breast
6.2.2 Invasive Ductal Carcinoma
6.2.3 Lobular Carcinoma
6.2.4 Triple Negative Breast Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Breast Cancer Diagnostic and Drug Technologies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Breast Cancer Diagnostic and Drug Technologies Analysis and Forecast
9.1 Introduction
9.2 North America Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Type
9.6.1 Mammography
9.6.2 Biopsy
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Applications
9.10.1 Ductal Carcinoma of Breast
9.10.2 Invasive Ductal Carcinoma
9.10.3 Lobular Carcinoma
9.10.4 Triple Negative Breast Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Breast Cancer Diagnostic and Drug Technologies Analysis and Forecast
10.1 Introduction
10.2 Europe Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Type
10.6.1 Mammography
10.6.2 Biopsy
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Applications
10.10.1 Ductal Carcinoma of Breast
10.10.2 Invasive Ductal Carcinoma
10.10.3 Lobular Carcinoma
10.10.4 Triple Negative Breast Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Breast Cancer Diagnostic and Drug Technologies Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Type
11.6.1 Mammography
11.6.2 Biopsy
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Applications
11.10.1 Ductal Carcinoma of Breast
11.10.2 Invasive Ductal Carcinoma
11.10.3 Lobular Carcinoma
11.10.4 Triple Negative Breast Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Breast Cancer Diagnostic and Drug Technologies Analysis and Forecast
12.1 Introduction
12.2 Latin America Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Type
12.6.1 Mammography
12.6.2 Biopsy
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Applications
12.10.1 Ductal Carcinoma of Breast
12.10.2 Invasive Ductal Carcinoma
12.10.3 Lobular Carcinoma
12.10.4 Triple Negative Breast Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Breast Cancer Diagnostic and Drug Technologies Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Type
13.6.1 Mammography
13.6.2 Biopsy
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Breast Cancer Diagnostic and Drug Technologies Market Size Forecast by Applications
13.10.1 Ductal Carcinoma of Breast
13.10.2 Invasive Ductal Carcinoma
13.10.3 Lobular Carcinoma
13.10.4 Triple Negative Breast Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Breast Cancer Diagnostic and Drug Technologies Market: Competitive Dashboard
14.2 Global Breast Cancer Diagnostic and Drug Technologies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott
14.3.2 Roche
14.3.3 BioMerieux
14.3.4 Becton Dickinson
14.3.5 GE Healthcare
14.3.6 Hologic
14.3.7 Philips
14.3.8 PerkinElmer
14.3.9 Quest Diagnostics
